United Therapeutics Corporation (NASDAQ:UTHR) Receives $461.62 Consensus Target Price from Analysts

United Therapeutics Corporation (NASDAQ:UTHR) has been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $501.90.

Several research analysts recently commented on the stock. Wells Fargo & Company raised their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Weiss Ratings restated a “hold (c+)” rating on shares of United Therapeutics in a report on Wednesday, October 8th. UBS Group increased their price target on United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a report on Monday, September 29th. Finally, Bank of America boosted their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 368,435 shares of company stock worth $152,863,012 over the last three months. 10.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after acquiring an additional 15,312 shares during the period. AQR Capital Management LLC grew its holdings in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares during the last quarter. Invesco Ltd. raised its holdings in shares of United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares during the period. Assetmark Inc. grew its holdings in shares of United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of United Therapeutics by 0.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock valued at $192,571,000 after purchasing an additional 4,145 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 1.8%

United Therapeutics stock opened at $445.43 on Friday. The stock has a fifty day moving average price of $410.07 and a 200 day moving average price of $338.35. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $479.50. The firm has a market capitalization of $20.09 billion, a P/E ratio of 16.88, a PEG ratio of 4.96 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company earned $6.39 EPS. As a group, equities analysts predict that United Therapeutics will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.